BRIEF published on 07/01/2024 at 09:27, 1 year 10 months ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
PRESS RELEASE published on 07/01/2024 at 09:22, 1 year 10 months ago Inside Information / Other news releases ABIONYX successfully completes a capital increase of c.€3.4 million through the issuance of shares with warrants. The fundraising aims to strengthen the company's cash position for its development in sepsis and the United States Fundraising Capital Increase Sepsis ABIONYX Shares With Warrants
BRIEF published on 06/27/2024 at 19:27, 1 year 10 months ago ABIONYX Pharma Achieves Unanimous Approval at Combined General Meeting Shareholders Biotech General Meeting Resolutions ABIONYX Pharma
PRESS RELEASE published on 06/27/2024 at 19:22, 1 year 10 months ago Inside Information / Other news releases ABIONYX Pharma announces unanimous approval of all resolutions at its Combined General Meeting. Shareholders renew mandates and approve buyback program Shareholders Buyback Program Renewal Combined General Meeting ABIONYX Pharma
BRIEF published on 06/19/2024 at 21:20, 1 year 10 months ago ABIONYX announces a capital increase without preferential subscription rights Biotechnology Actions United States Increase In Capital Sepsis
PRESS RELEASE published on 06/19/2024 at 21:15, 1 year 10 months ago Inside Information / Other news releases ABIONYX announces capital increase of c.€3.4 million with share issuance and warrants, strengthening financial position for Sepsis and US development, supported by ORSAY 53 investment company Capital Increase Share Issuance ABIONYX Sepsis Development ORSAY 53
BRIEF published on 06/13/2024 at 19:53, 1 year 10 months ago ABIONYX Pharma Receives FDA Approval for New Sepsis Study FDA Clinical Study ABIONYX Pharma Sepsis CER-001
PRESS RELEASE published on 06/13/2024 at 19:48, 1 year 10 months ago Inside Information / Other news releases ABIONYX Pharma completes successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial in Sepsis, marking significant progress in developing innovative therapy FDA ABIONYX Pharma Sepsis CER-001 Pre-IND Meeting
Published on 05/02/2026 at 00:00, 39 minutes ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 39 minutes ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/01/2026 at 22:30, 2 hours 9 minutes ago Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 22:30, 2 hours 9 minutes ago Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing
Published on 05/01/2026 at 22:30, 2 hours 9 minutes ago Apex Critical Metals Announces Extension of Marketing Agreement with Rumble Strip Media Inc.
Published on 05/01/2026 at 19:23, 5 hours 16 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 17:45, 6 hours 54 minutes ago Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 7 hours 18 minutes ago Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 04/30/2026 at 20:00, 1 day 4 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 5 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 5 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 6 hours ago Minutes of the Combined General Meeting held on April 30, 2026
